Related Experiment Video
Updated: May 4, 2026
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Preliminary assessment of zolpidem pharmacokinetics in pediatric burn patients
Chris Stockmann1, Catherine M T Sherwin, Whitney Buterbaugh
1*Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City; †James L. Winkle College of Pharmacy, University of Cincinnati; ‡The Shriners Hospitals for Children; and §Department of Surgery, University of Cincinnati, OH.
Insights
This study developed a pharmacokinetic model for zolpidem in burned children to improve sleep. The model helps understand how zolpidem is processed in this patient population.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Burn Injury Management
Background:
- Severely burned children often suffer from sleep disturbances, including insomnia and fragmented sleep.
- Effective sleep management is crucial for recovery and well-being in pediatric burn patients.
Purpose of the Study:
- To evaluate the population pharmacokinetics of zolpidem, a sleep-enhancing medication, in pediatric patients with severe burns.
- To establish a pharmacokinetic model for zolpidem in this specific patient group.
Main Methods:
- Zolpidem was administered based on age-specific doses (2.5-10 mg).
- Serum samples were collected at multiple time points post-administration (0-8 hours).
- Population pharmacokinetic analysis was performed using nonlinear mixed-effects models.
Main Results:
- Eleven pediatric burn patients (mean age 8.3 years, 56% burn surface area) were included.
- A two-compartment model with first-order absorption best described zolpidem concentrations.
- Zolpidem clearance increased with body weight, and volume of distribution was inversely related to third-degree burn surface area.
Conclusions:
- A reliable population pharmacokinetic model for zolpidem in pediatric burn patients was successfully developed.
- Further research is needed to correlate this model with pharmacodynamic data, including effects on sleep architecture.
- Future studies may explore higher doses or more frequent zolpidem administration for improved sleep outcomes.
Purpose:
Severely burned patients frequently experience sleep fragmentation and insomnia. This study evaluated the population pharmacokinetics of the sleep-enhancing agent zolpidem among burned children.
Methods:
Zolpidem was administered according to the following age-based dosing schedule: 2.5 mg per dose for 2-4 year olds, 5.0 mg per dose for 5-10 year olds, and 10 mg per dose for older than 10 years. Serum samples were collected before and 1, 2, 4, 5, 6, and 8 hours after dosing. The population pharmacokinetic analysis modeled zolpidem concentrations using nonlinear mixed effects models.
Results:
Eleven patients with a mean (±SD) age of 8.3 ± 4.0 years and a mean total burn surface area of 56% ± 22% were recruited. Seventy-three zolpidem concentrations were measured with a mean Cmax of 291 ± 140 ng/mL. A 2-compartment model with first-order absorption best described the data. Zolpidem clearance was estimated at 0.03 L·h(-1)·kg(-1) (relative standard error, 55%) and increased with body weight (P < 0.05). The central compartment volume of distribution was estimated at 0.05 L/kg (relative standard error, 25%), which was inversely related to the proportion of the body surface with third-degree burns (P < 0.001).
Conclusions:
A population pharmacokinetic model has been developed that reliably characterized the pharmacokinetic parameters of zolpidem when used as a sleep-enhancing agent among pediatric burn patients. Additional studies are needed to link this pharmacokinetic model with pharmacodynamic data, which may include an assessment of the effects of higher zolpidem doses and/or more frequent administration upon sleep architecture.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
08:49Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
Published on: October 16, 2013
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:29Drug Dosing: Infants and Children
01:27Pharmacodynamics in Geriatric Patients: Effects of Age